Souhaitez-vous accéder aux communiqués récents ?

Elevara Medicines announces dosing of the first patient in its Phase 2b START-SYNERGY clinical trial evaluating ELV001, a novel oral CDK4/6 inhibitor.

FDA cleared Urocross, a non-permanent BPH implant. It remodels tissue for 6 months, then is intentionally retrieved, leaving no permanent implant behind.

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update Phase 2 interim results suggest treatment with active immunotherapy ACI-7104 may slow the progression of Parkinson’s...

All three patients in 60 Degrees Pharma’s expanded access study were cured of relapsing babesiosis after tafenoquine treatment, supporting guideline review

New $40 million raise brings Series A total to $100M, enabling advancement of VIM0423, a first-in-class oral therapeutic, into Phase 2 trials for isolated dystonia and for Parkinson’s diseaseFirst...

Egg Medical's Late-Breaker at CRT 2026 proves the EggNest™ reduces scatter radiation, allowing the interventional team to safely work lead-apron free.

The purpose of the study will be used as an important tool to measure the concentration of PRP and its analytes over time upon administration to patients

Kainova Therapeutics announces positive Phase I results for DT‑9081, showing strong safety, target engagement and early anti‑tumor activity.

Phase 1/2 RESTORE-MASH trial will evaluate safety, pharmacokinetics, and pharmacodynamics of TGM-312 in healthy volunteers and MASH patients Initial data anticipated H2 2026 LONDON, March 05, 2026 ...

Herantis Pharma Plc | Company Release | March 5, 2026 at 08:00:00 EET Espoo, Finland, March 5, 2026: Herantis Pharma Plc ("Herantis") a clinical-stage company developing disease-modifying therapies...